Neion Bio secures $23M Series A to develop egg-based protein platform for biologics
read at Endpoints ↗DealPositive
Neion Bio announced it closed a $23 million Series A round that was oversubscribed.
The funding will be used to advance its platform that leverages chicken eggs, extracting primordial germ cells from fertilized eggs to produce active pharmaceutical ingredients for biologic medicines.
The approach aims to provide an alternative manufacturing route for biologics, potentially reducing reliance on traditional cell‑culture methods.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Neion Bio raises $23M Series A to make proteins from chicken eggs”
read at Endpoints ↗100 words · retrieved Jun 11
comments(0)
5-min edit window · permanent after that